| 25-Oct-2004 - New
oral vaccine for Alzheimer's disease
Alzheimer's disease is characterized
by progressive loss of cognitive function due to amyloid-beta (Aß)
deposits in the central nervous system. If these deposits could be stopped
or slowed, Alzheimer's disease might become more manageable. In the current
issue of the Journal of Alzheimer's Disease, a novel paper from researchers
from the National Institute for Longevity Sciences, NCGG, Japan and Center
for Neurological Diseases, Brigham & Women's Hospital, Harvard Institute
of Medicine shows that a new oral vaccine treatment is effective in reducing
Alzheimer's disease pathology.
Immunization results from the production of antibodies
which attack the harmful agent, using the body's own defenses to remove
the threat. In an earlier immunization study, 6 percent of the subjects
developed acute meningoencephalitis, most likely caused by autoimmune
T-cell activation. This caused the trial to be stopped. By developing
vaccines that can minimize this T-cell activation while retaining the
production of Aß-antibodies, a safer treatment might result.
The researchers attached Aß DNA to an adeno-associated
virus vector and administered this vaccine to mice orally. Not only were
the Aß levels decreased, but the T-cell immune response was significantly
reduced. A single dose of this vaccine enhanced the production of Aß-antibodies
for more than 6 months. Immunohistochemistry of the mouse brain tissue
showed that the extra-cellular amyloid deposits were clearly decreased
compared to the non-treated mouse.
Hideo Hara, M.D, writes "This new oral vaccine does
not induce strong T cell immune reactions, and hence it could reduce the
side effect of such meningoencephalitis…This new therapy seems to
be effective for prevention and treatment of Alzheimer's disease."
The article is "Development of a safe oral Aß
vaccine using recombinant adeno-associated virus vector for Alzheimer's
disease" by Hideo Hara, Alon Monsonego, Katsutoshi Yuasa, Kayo Adachi,
Xiao Xiao, Shin'ichi Takeda, Keikichi Takahashi, Howard L. Weiner and
Takeshi Tabira. It appears in the Journal of Alzheimer's Disease, Vol.6,
Number 5, published by IOS Press.
Full Release - http://www.eurekalert.org/pub_releases/2004-10/cwru-nov102504.php
Back to Press Releases
|